271 related articles for article (PubMed ID: 28208219)
1. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma.
Gassiot S; Motlló C; Llombart I; Morgades M; González Y; Garcia-Caro M; Ribera JM; Oriol A
Eur J Haematol; 2017 Jun; 98(6):569-576. PubMed ID: 28208219
[TBL] [Abstract][Full Text] [Related]
2. Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
Lee SE; Yoon JH; Shin SH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Min CK
Ann Hematol; 2014 Apr; 93(4):627-34. PubMed ID: 24085241
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Pérez R; Durán MS; Mayans J; Soler A; Castillo I; Jurado M; Ribas P; Menchaca Echevarria MC; Hernandez MT; Lopez Garcia-Carreño MD; Echeveste Gutierrez A; Bailen Garcia A; Lopez S; Baquero J; Ramirez G
Eur J Haematol; 2016 Apr; 96(4):417-24. PubMed ID: 26190662
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
5. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
6. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
7. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
8. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
Br J Haematol; 2018 Jul; 182(1):71-77. PubMed ID: 29707759
[TBL] [Abstract][Full Text] [Related]
9. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
10. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
12. Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Hock BD; Mulholland KS; Ganly P; McKenzie JL; Pearson JF; MacPherson SA
Intern Med J; 2019 May; 49(5):598-606. PubMed ID: 30411451
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry.
Huang TC; Huang SY; Yao M; Lin CY; Hwang WL; Gau JP; Tan TD; Wang PN; Liu YC; Lin SC; Kao RH; Pei SN; Yu MS; Lin HY; Su YC; Chen CC; Li SS; Wu YY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):471-480. PubMed ID: 30119948
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M
Eur J Haematol; 2005 Nov; 75(5):391-5. PubMed ID: 16191088
[TBL] [Abstract][Full Text] [Related]
15. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Kaufman GP; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Lust JA; Russell S; Go RS; Hwa YL; Kyle RA; Rajkumar SV; Kumar SK
Leukemia; 2016 Mar; 30(3):633-9. PubMed ID: 26487275
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
17. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
[TBL] [Abstract][Full Text] [Related]
19. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma-Effect of Induction Therapy on Transplant Outcomes.
Kumar L; Gundu N; Kancharia H; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma O; Biswas A; Kumar R; Thulkar S; Mallick S;
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):80-90.e5. PubMed ID: 33129746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
